PRESS RELEASE. Sciety has strengthened the board of its portfolio company PeptiSystems by appointing Nick Roelofs – a strategic addition that significantly enhances the company’s ability to scale global sales and build strong industrial partnerships within advanced pharmaceutical manufacturing. The appointment is part of Sciety’s broader strategy to actively contribute specialist expertise to its portfolio companies.
Nick Roelofs was elected to the board at PeptiSystems’ annual general meeting following a nomination by Sciety. His international experience and commercial expertise are a strong match for the company’s needs in a phase where its technology is validated, the market is expanding rapidly, and commercialisation is accelerating.
PeptiSystems develops innovative synthesis instruments for efficient, large-scale manufacturing of peptide- and oligonucleotide-based drugs – a sector experiencing rapidly growing global demand.
Nick Roelofs brings over 40 years of international leadership experience in the life science industry, with a particular focus on advanced analytical instruments, diagnostics, and the commercialisation of research-intensive technologies. Holding a PhD in chemistry, Nick has led growth journeys at several global companies in the life science tools sector, where highly specialised technologies are brought to international markets. As President of the Life Sciences Group at Agilent Technologies, he oversaw a business unit with approximately USD 3 billion in annual revenue and was responsible for both organic growth and acquisitions – including the Swedish company Halo Genomics and the Danish firm DAKO. At Bio-Rad Laboratories, he helped shape the company’s innovation strategy and market expansion
Nick has also served as an advisor to Summa Equity and Nordic Capital, where he had key roles in strategic investments in companies such as Olink – including its USD 3.1 billion sale to Thermo Fisher.
“Nick brings a rare combination of scientific expertise, international business experience and strategic insight. His strong background in building and leading global organisations makes him a valuable addition to PeptiSystems’ board. His experience will be particularly important as the company continues its international expansion and meets the growing global demand for advanced manufacturing solutions in the peptide and oligonucleotide field,” says Andreas Lindblom, Managing Partner at Sciety.
“Nick has extensive experience in commercialising advanced instrumentation and understands what it takes to succeed internationally. His insights will provide concrete support as we continue our growth journey and engage with strategic partners.” says Karin Granath, CEO of PeptiSystems.
For further information, please contact:
Andreas Lindblom, Managing Partner, Sciety: andreas.lindblom@sciety.se, phone: +46 70 375 73 73
Karin Granath, VD, PeptiSystems: karin.granath@peptisystems.com, phone: +46 702 82 07 47
_________________________________________________
About PeptiSystems
PeptiSystems is a biotech company offering a new generation of flow-through instruments for peptide and oligonucleotide therapeutics synthesis. Leveraging proprietary flow-through column technology, PeptiSystems’ instruments significantly reduce production times, enhance synthesis control, and minimise raw material consumption while maintaining high purity and yield. With scalability in mind, these next-generation synthesis instruments seamlessly adapt from small-scale development to large-scale production, enabling pharmaceutical companies and CDMOs to meet the growing global demand for efficient, cost-effective, and sustainable manufacturing processes. PeptiSystems is headquartered in Uppsala, Sweden. For more information, visit peptisystems.com and follow Peptisystems on LinkedIn.
About Sciety
Sciety is a leading investment company, committed to supporting the growth of innovative life science and health tech companies in the Nordic region. We invest alongside Sciety Venture Partners, comprising family offices and private investors, as well as venture capital firms. Our mission is to enable the full potential of life science innovations, helping to bring breakthroughs in healthcare to people all over the world. For more information visit sciety.com and follow Sciety on Linkedin.
Receive news and invitations from Sciety
Join our newsletter to be the first to know about new investment opportunities and receive invitations to company presentations, seminars, and events.
Disclaimer: The information contained in our emails and communications is intended for informational purposes only and is not intended to constitute advice or recommendations on any investment. We do not guarantee the accuracy, completeness, timeliness, or suitability of any information provided. Please note that our communications are not intended for distribution to, or use by, any person or entity in any jurisdiction or country where such distribution or use would be contrary to local law or regulation. In particular, our communications are not intended for persons in the United States or Australia. We do not accept any liability for any loss or damage arising from the use of our communications, including but not limited to any investment decisions made based on the information provided. Furthermore, please note that any investment in private companies involves a high degree of risk and is not suitable for all investors. Before making any investments, you must read and accept our general terms and conditions for investments, which can be found at the following link: General Terms and Conditions for Investments.
Latest news
